Cetuximab monotherapy in advanced cervical cancer: a retrospective study with five patients


Effective cytotoxic treatment options for advanced cervical cancer are exceedingly limited. Therefore, interest has increased in targeted therapeutics for the treatment of cervical cancer. Cetuximab, a monoclonal antibody, binds specifically to the epidermal growth factor receptor (EGFR) and competitively inhibits the binding of epidermal growth factor and… (More)
DOI: 10.1007/s00404-010-1389-1

4 Figures and Tables


  • Presentations referencing similar topics